Fight Aging! Newsletter, June 6th 2022
This study examines evidence suggesting that mitochondrial dysfunction plays a significant early impact on AD pathology.
Although mitochondrial dysfunction is a typical indication of Alzheimer's disease, it is unclear whether the cellular systems that maintain mitochondrial integrity malfunction, aggravating mitochondrial pathology. Different levels of vigilance and preventive methods are used to reduce mitochondrial damage and efficiently destroy faulty mitochondria to maintain the mitochondrial equilibrium. The form and function of mitochondria are regulated by mitochondrial fusion and fission. In contrast, mitoch...
Source: Fight Aging! - June 5, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
SGLT2 Inhibition Reduces Vascular Dysfunction in Aged Mice
We report that Empa-treated mice exhibited improved mesenteric endothelial function compared with control, in parallel with reduced mesenteric artery and aortic stiffness. Our findings demonstrate that Empa improves endothelial function and reduces arterial stiffness in a preclinical model of aging, making SGLT2 inhibition a potential therapeutic alternative to reduce the progression of cardiovascular disease in older individuals.
Link: https://doi.org/10.1007/s11357-022-00563-x (Source: Fight Aging!)
Source: Fight Aging! - June 1, 2022 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
EMPEROR-Preserved Clinical Trial Review
EMPEROR-Preserved Clinical Trial is an important study which has shown benefit in patients with heart failure and a preserved ejection fraction (HFpEF) [1].
It was a double blind randomized trial in which 5988 patients with class II-IV heart failure and ejection fraction above 40% were allocated to receive empagliflozin 10 mg daily or placebo, in addition to usual therapy.
The median ejection fraction noted in the study patients was 54%, with two thirds of patients having a left ventricular ejection fraction of 50% or more.
Primary outcome measure in the study was a composite of cardiovascular death or hospitalization for...
Source: Cardiophile MD - September 2, 2021 Category: Cardiology Authors: Prof. Dr. Johnson Francis Tags: Cardiology Source Type: blogs
Type 2 diabetes: Which medication is best for me?
If you are living with type 2 diabetes, you certainly are not alone. One in 10 people in the US has diabetes, according to the CDC. However, despite considerable progress in diabetes treatment over the past 20 years, fewer than half of those with diabetes actually reach their target blood sugar goal.
In part, this may be because doctors can be slow to make changes to a patient’s treatment plan, even when a patient’s treatment goals are not being met. One reason for this may be the overwhelming number of medications currently available. And yet, waiting too long to adjust treatment for type 2 diabetes can have long-last...
Source: Harvard Health Blog - November 5, 2020 Category: Consumer Health News Authors: Samar Hafida, MD Tags: Diabetes Drugs and Supplements Source Type: blogs
Doctors shouldn ’t be horse whisperers
I scribbled my signature on a pharmaceutical rep ’s iPad today for some samples of Jardiance, a diabetes drug that now has expanded indications, according to the Food and Drug Administration. This drug lowers blood sugar (reduces HbA1c by less than 1 point) but also reduces diabetes-related kidney damage, heart attacks, strokes and now also admi ssion […]Find jobs at Careers by KevinMD.com. Search thousands of physician, PA, NP, and CRNA jobs now. Learn more. (Source: Kevin, M.D. - Medical Weblog)
Source: Kevin, M.D. - Medical Weblog - November 28, 2019 Category: General Medicine Authors: < span itemprop="author" > < a href="https://www.kevinmd.com/blog/post-author/a-country-doctor" rel="tag" > Hans Duvefelt, MD < /a > < /span > Tags: Physician Cardiology heart failure Primary Care Source Type: blogs
More and More Pills for 25-30% Better Odds of This, That and The Other – Some Patients Want That, and Some Will Run the Other Way
By HANS DUVEFELT, MD
I scribbled my signature on a pharmaceutical rep’s iPad today for some samples of Jardiance, a diabetes drug that now has expanded indications according to the Food and Drug Administration. This drug lowers blood sugar (reduces HbA1c by less than 1 point) but also reduces diabetes related kidney damage, heart attacks, strokes and now also admission rates for heart failure (from 4.1% to 2.7% if I remember correctly – a significant relative risk reduction but not a big absolute one; the Number Needed to Treat is about 70, so 69 out of 70 patients would take it in vain for the heart failure indicat...
Source: The Health Care Blog - November 13, 2019 Category: Consumer Health News Authors: Christina Liu Tags: Medical Practice Patients Physicians Primary Care Hans Duvefelt Source Type: blogs
Join the Undoctored Revolution
Let’s take back control over personal health. Share this to expose healthcare for the corrupt enterprise it is.
Imagine that you receive a letter in the mail stating “In order to retain your right to freedom of speech, you will be billed $10,000 per year every year for the rest of your life.”
You would be—-understandably-—outraged. Freedom of speech in America is precious, something Americans have waged wars to defend, something we now view as a basic right, no financial price required to maintain it. It should be free and available to everyone regardless of religion, color, political leanings, or income.
...
Source: Wheat Belly Blog - February 9, 2018 Category: Cardiology Authors: Dr. Davis Tags: Undoctored Wheat Belly Lifestyle diy health Dr. Davis grain-free healthcare Source Type: blogs
How does SGLT2 inhibition improve heart failure?
How does Sodium Glucose Cotransporter-2 (SGLT2) inhibition improve heart failure?
Different ways by which SGLT2 inhibition can improve heart failure are:
Natriuresis
Osmotic diuresis
These in turn leads to reduction of plasma volume and preload. An associated decrease in blood pressure, after load and arterial stiffness follows. Reduction in afterload can improve subendocardial blood flow as well.
SGLT2 inhibitors are a new class of oral hypoglycemic agents. EMPA-REG OUTCOME trial with Empagliflozin (Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) and CANVAS trial (Canagliflozin Cardiovascular As...
Source: Cardiophile MD - October 27, 2017 Category: Cardiology Authors: Johnson Francis Tags: General Cardiology Source Type: blogs
Health should be FREE
Imagine that you receive a notice in the mail stating “In order to maintain your freedom of speech, you will be billed $10,000 per year.”
You would be—understandably—outraged. Freedom of speech in America is precious, something Americans have fought wars to defend. We view free speech as a basic right, no big check to write in order to maintain it. It should be free and available to everyone regardless of religion, color, political leanings, or income.
I believe that same principle should apply to health.
Being healthy means living free of common chronic health conditions such as high cholesterol, high blood sugars...
Source: Wheat Belly Blog - March 31, 2017 Category: Cardiology Authors: Dr. Davis Tags: Undoctored crowd wisdom health free Healthcare System predatory wheat belly Source Type: blogs
Cleveland Clinic's Top Ten Medical Innovations for 2017; Focus on FHIR
The Cleveland Clinic lists its choices on a yearly basis for the top ten medical innovations. It recently posted its 2017 list (see:Cleveland Clinic names top 10 medical innovations 2017):The microbiome. The microbiome is made up of trillions of helpful bacteria that make a home inside the human gut – to prevent, treat and diagnose disease.Diabetes drugs that reduce heart disease and death....Novo Nordisk ’s liraglutide, sold as Victoza, and Eli Lilly’s empagliflozin, sold as Jardiance, have shown promise in reducing these heart-related complications (see:Novo Slumps as Study on Victoza ’s Heart Impact Disappoints)...
Source: Lab Soft News - October 31, 2016 Category: Laboratory Medicine Authors: Bruce Friedman Tags: EHR Electronic Health Record (EHR) Healthcare Business Healthcare Delivery Healthcare Information Technology Hospital Executive Management Standards Source Type: blogs
Prominent Cardiologists Decry Tepid Support For Empagliflozin By Endocrinologists
At the FDA advisory panel empagliflozin enjoyed strong support from the cardiologists and statisticians but not from the endocrinologists. An FDA advisory panel last week turned out to be a much more contentious and divided than many had expected. Based on the FDA’s own analysis of last year’s Empa-Reg Outcome trial I had predicted that the...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - July 5, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics CVOT diabetes empagliflozin FDA advisory panel glucose Source Type: blogs
Empagliflozin May Be Poised To Gain CV Indication
–FDA reviewers have raised no major questions ahead of Tuesday’s advisory panel meeting. The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will likely lend its support to an important new expanded indication for empagliflozin (Jardiance, Boehringer Ingelheim). The new indication is to reduce the risk of all-cause mortality by reducing the incidence of cardiovascular death,...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - June 24, 2016 Category: Cardiology Authors: Larry Husten Tags: Diabetes People, Places & Events advisory panel CVOT empagliflozin FDA outcomes trials Source Type: blogs
Time For Cardiologists To Start Prescribing Diabetes Drugs?
There’s an emerging consensus that now may be the time for cardiologists to start thinking seriously about prescribing diabetes drugs. Until now most cardiologists have not considered this to be part of their job description. But now new data from large cardiovascular outcome trials (CVOTs) shows that these drugs may one day become, like statins and...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - June 22, 2016 Category: Cardiology Authors: Larry Husten Tags: Diabetes Policy & Ethics Prevention, Epidemiology & Outcomes Uncategorized diabetes drugs empagliflozin liraglutide Source Type: blogs
Companies Plan To Study Diabetes Drug In Heart Failure Population
–New attention paid to the intersection of heart failure and diabetes Boehringer Ingelheim and Eli Lilly announced on Wednesday that they were planning two separate outcomes trials to test the effect of the diabetes drug empagliflozin (Jardiance) in patients with chronic heart failure. The trials herald a remarkable shift in emphasis, since there have been...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - April 21, 2016 Category: Cardiology Authors: Larry Husten Tags: Diabetes Heart Failure People, Places & Events empagliflozin Jardiance Source Type: blogs
A Year in Review: FDA 2015 New Drug Approvals
The approval of first-of-a-kind drugs rose last year to forty-one, resulting in the highest level of newly approved U.S. drugs in nineteen years. The total number of new drugs approved last year was even higher at sixty-nine. The rising figures reflect an industry-wide desire to research and develop drugs for rare and hard-to-treat diseases.
The newly approved drugs serve to advance medical care and the health of patients suffering from many ailments, including various forms of cancer, heart failure, and cystic fibrosis. Additionally, more than 40% of the new therapies were approved for treatment of rare or "orphan" dise...
Source: Policy and Medicine - January 13, 2016 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
